Knowledge, attitudes, and practices of business travelers regarding influenza and the use of antiviral medication.

BACKGROUND This study aimed to determine the knowledge, attitudes, and practices of Swiss business travelers with regard to influenza and the use of antiviral medication. METHODS Questionnaires, available in three languages, were distributed manually and online through companies, organizations, and travel medicine specialists in Switzerland to business travelers who were traveling during the period January 2005 to April 2009. RESULT In total, 661 questionnaires were fully completed and evaluated. A total of 58.9% (n = 388) of the respondents stated that they had contracted influenza in the past; some 48.6% (n = 321) of the travelers had been vaccinated against seasonal influenza at least once in their lifetime; 87.1% (n = 576) of the travelers knew that influenza can be transmitted by droplets; and 62.3% (n = 412) were aware of transmission by direct contact. Almost all respondents (96.8%; n = 633) recognized fever as a main symptom of influenza, 80.0% (n = 523) knew about muscular aches and pain, 79.5% (n = 520) about shivering, and 72.9% (n = 477) about joint pain. Some 38.0% (n = 250) of the respondents stated that the annual vaccination is their preferred prevention method for influenza, 35.6% (n = 234) would neither do an annual vaccination nor carry antiviral medication, 16.0% (n = 105) would carry antiviral medication, 8.5% (n = 56) would prefer to do both the annual vaccination and to carry antivirals, and 2.0% (n = 13) would use antivirals as influenza prophylaxis. Regarding prevention, the majority (78.9%; n = 498) of the travelers did not seek advice on influenza before going on their last business trip, 58.0% (n = 381) did not take any preventive measures against influenza, 27.2% (n = 179) had their annual vaccination, and 15.7% (n = 103) observed hand hygiene. Of the travelers, 9.7% (n = 64) carried antiviral medication on their last business trip and 7.0% (n = 46) actually used this medication. CONCLUSIONS Business travelers have a good knowledge about the transmission and the symptoms of influenza but guidelines are needed that concisely address the indications for influenza vaccination in travelers and the carriage and use of antiviral medication.

[1]  [Traveller's medicine on the Internet]. , 2005, Ugeskrift for laeger.

[2]  Mary E. Wilson,et al.  Fever in returned travelers: results from the GeoSentinel Surveillance Network. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Mary E. Wilson,et al.  Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. , 2010, Vaccine.

[4]  G. Chowell,et al.  Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? , 2010, BMC infectious diseases.

[5]  M. Mutsch,et al.  Influenza vaccine: a travelers’ vaccine? , 2008, Expert review of vaccines.

[6]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[7]  G. Zuccotti,et al.  The evolution of influenza resistance and treatment. , 2009, JAMA.

[8]  Karin Leder,et al.  Influenza: changing approaches to prevention and treatment in travelers. , 2006, Journal of travel medicine.

[9]  S. Ansart,et al.  Grippe et voyage , 2006, Médecine et Maladies Infectieuses.

[10]  Lynnette Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[11]  Pratik Mukherjee,et al.  Epidemiology of Travel-associated Pandemic (H1N1) 2009 Infection in 116 Patients, Singapore , 2010, Emerging infectious diseases.

[12]  Chaug-Ing Hsu,et al.  Transmission and control of an emerging influenza pandemic in a small-world airline network , 2009, Accident Analysis & Prevention.

[13]  J. Mossong,et al.  Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  Sally Blower,et al.  Calculating the potential for within-flight transmission of influenza A (H1N1) , 2009, BMC medicine.

[15]  A. Kelso,et al.  Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation , 2009, Journal of Virology.

[16]  Karin Leder,et al.  Respiratory tract infections in travelers: a review of the GeoSentinel surveillance network. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  C. Drosten,et al.  Spectrum of Viruses and Atypical Bacteria in Intercontinental Air Travelers with Symptoms of Acute Respiratory Infection , 2007, The Journal of infectious diseases.

[18]  A. Hay,et al.  Influenza virus infection in travelers to tropical and subtropical countries. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  A. Nitsch-Osuch.  Influenza as a health problem of sea travellers. , 2008, International maritime health.